Gettinger, S. N., Hellmann, M. D., Shepherd, F. A., Antonia, S. J., Brahmer, J., Chow, L. Q., … Rizvi, N. (2015). 3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses. In European Journal of Cancer (Vol. 51, pp. S632–S632). Elsevier BV. https://doi.org/10.1016/s0959-8049(16)31737-3

Gettinger, S. N., M. D. Hellmann, F. A. Shepherd, S. J. Antonia, J. Brahmer, L. Q. Chow, J. Goldman, et al. “3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses.” In European Journal of Cancer, 51:S632–S632. Elsevier BV, 2015. https://doi.org/10.1016/s0959-8049(16)31737-3.

Gettinger SN, Hellmann MD, Shepherd FA, Antonia SJ, Brahmer J, Chow LQ, et al. 3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses. In: European Journal of Cancer. Elsevier BV; 2015. p. S632–S632.

Gettinger, S. N., et al. “3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses.” European Journal of Cancer, vol. 51, Elsevier BV, 2015, pp. S632–S632. Crossref, doi:10.1016/s0959-8049(16)31737-3.

Gettinger SN, Hellmann MD, Shepherd FA, Antonia SJ, Brahmer J, Chow LQ, Goldman J, Juergens R, Borghaei H, Ready NE, Gerber DE, Nathan F, Shen Y, Harbison CT, Rizvi N. 3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses. European Journal of Cancer. Elsevier BV; 2015. p. S632–S632.